| Identification | Back Directory | [Name]
I-CBP112 | [CAS]
1640282-31-0 | [Synonyms]
CS-2420
I-CBP112
I-CBP112, >98%
I-CBP112, 1640282-31-0
I-CBP112 hydrochloride
I-CBP112; I-CBP-112; I-CBP 112
1-Propanone, 1-[7-(3,4-dimethoxyphenyl)-2,3-dihydro-9-[[(3S)-1-methyl-3-piperidinyl]methoxy]-1,4-benzoxazepin-4(5H)-yl]-
1-[7-(3,4-Dimethoxyphenyl)-9-[[(3S)-1-methylpiperidin-3-yl]methoxy]-2,3,4,5-tetrahydro-1,4-benzoxazepin-4-yl]propan-1-one | [Molecular Formula]
C27H36N2O5 | [MDL Number]
MFCD26792587 | [MOL File]
1640282-31-0.mol | [Molecular Weight]
468.59 |
| Chemical Properties | Back Directory | [Boiling point ]
623.5±55.0 °C(Predicted) | [density ]
1.129±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO:63.0(Max Conc. mg/mL);134.44(Max Conc. mM)
Ethanol:94.0(Max Conc. mg/mL);200.6(Max Conc. mM)
Water:94.0(Max Conc. mg/mL);200.6(Max Conc. mM) | [form ]
powder | [pka]
9.07±0.10(Predicted) | [color ]
white to beige | [InChIKey]
YKNAKDFZAWQEEO-IBGZPJMESA-N | [SMILES]
CN(C1)CCC[C@@H]1COC2=CC(C3=CC=C(OC)C(OC)=C3)=CC4=C2OCCN(C(CC)=O)C4 |
| Safety Data | Back Directory | [Symbol(GHS) ]
GHS09 | [Signal word ]
Warning | [Hazard statements ]
H410 | [Precautionary statements ]
P273-P501 | [RIDADR ]
UN 3077 9 / PGIII | [WGK Germany ]
3 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Aquatic Acute 1
Aquatic Chronic 1 |
| Hazard Information | Back Directory | [Uses]
I-CBP112 has been used in cell culture and sample preparation, to verify the acetylation of VPS34 (vacuolar protein sorting 34), by p300 at K29, K771 and K781 and to diminish synergistic gene expression. | [Biochem/physiol Actions]
I-CBP112 is a selective inhibitor of the bromodomain-containing transcription factors CREBBP (CBP) and EP300 (IC50 = 0.142 and 0.625 μM, respectively). I-CBP112 has little activity against other bromodomains at concentrations up to 1 mM. For full characterization details, please see I-CBP112 on the Structural Genomics Consortium (SGC) website.To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc | [in vivo]
I-CBP112 significantly reduces the leukemia-initiating potential of mLL-AF9+ AmL cells in a dose-dependent manner in vitro and in vivo. The synergistic effects of I-CBP112 and current standard therapy (doxorubicin) as well as emerging treatment strategies (BET inhibition) provide new opportunities for combinatorial treatment of leukemia and potentially other cancers[2]. | [IC 50]
CBP/p300 | [storage]
+4°C |
|
| Company Name: |
Sigma-Aldrich
|
| Telephone: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
|